When LDL and ApoB Disagree: What Your Cholesterol Results Are Really Saying

I’ve been reading about cholesterol, specifically LDL-C and ApoB, and there’s something quite interesting about how we interpret these numbers.

Most of us have heard of LDL cholesterol. It’s usually one of the first things we look for in a lipid report, along with HDL and triglycerides. And if the numbers fall within the laboratory’s reference range, there’s a certain relief that comes with it.

Okay, cholesterol is fine. One less thing to worry about.

But what if that number isn’t telling us everything?

This is where ApoB comes in, and where LDL and ApoB disagreement starts to matter.

LDL-C measures how much cholesterol is being carried inside LDL particles. ApoB gives us an estimate of how many particles capable of contributing to plaque buildup are circulating in our blood.

Now, I initially wondered why we needed two measurements for what seemed like the same thing.

They’re measuring two different aspects of cholesterol transport. And while the numbers generally move together, LDL and ApoB disagreement does happen.

You could have a perfectly reasonable LDL-C result and still have an elevated ApoB. Or you could have high LDL-C with an ApoB result that is relatively lower than expected.

Both tests could be correct.

Which brings me to the question that got me interested in this subject in the first place. If two tests are measuring something related to cardiovascular health, and they’re telling us different things, which one do we pay attention to?

And more importantly, what are we missing when we only look at one?

If you’re trying to understand LDL and ApoB disagreement, the short answer is this: LDL-C tells you how much cholesterol is being carried, while ApoB reflects how many atherogenic particles are circulating. When those numbers do not match, ApoB often gives a clearer view of particle-related cardiovascular risk.

What Exactly Are LDL-C And ApoB Measuring?

I think it’s important to  understand a little bit about how cholesterol moves around in our bodies before getting into why these numbers disagree.

Cholesterol doesn’t travel freely through our blood. It needs to be transported by particles called lipoproteins.

LDL, or low-density lipoprotein, is one of them.

LDL-C tells us how much cholesterol is being carried inside these LDL particles.

ApoB, short for apolipoprotein B, is a protein found on LDL and on the other particles that can contribute to plaque buildup in arteries. VLDL, IDL, the remnants left behind as those particles are processed, and lipoprotein(a).

Each of these particles carries exactly one ApoB protein. Chylomicron remnants carry a shorter version called ApoB48, and the rest carry ApoB100, but the principle holds. One particle, one protein.

Which is what makes ApoB such an effective measurement. It isn’t estimating cholesterol and working backwards; it’s counting protein tags, and each tag represents one particle.

Now imagine two people with the same amount of LDL cholesterol.

One person could have fewer LDL particles, each carrying quite a bit of cholesterol. The other could have many more particles, each carrying a smaller amount.

Their LDL-C results could look similar, but their ApoB results might be quite different.

And this distinction becomes important because the particles themselves can enter artery walls, become retained there, and contribute to atherosclerosis, the process through which plaque builds up over time.

Having more of these particles circulating means more opportunities for that to happen.

So the amount of cholesterol being carried matters. But the number of particles carrying it tells us something else about our cardiovascular risk.

One thing I didn’t know about LDL-C

Here’s a detail I found genuinely surprising, and if you’re trying to make sense of a lipid report.

In most laboratories, LDL-C isn’t actually measured.

It’s calculated from total cholesterol, HDL-C and triglycerides. The traditional Friedewald equation has a known weakness: it underestimates LDL-C as triglycerides rise, and the estimate is also affected by whether the sample was taken after a meal. Newer equations, such as Martin/Hopkins and Sampson-NIH, reduce that error considerably, but they don’t remove it entirely, and not every laboratory has adopted them.

What Happens When LDL-C And ApoB Disagree?

There’s actually a term for this: discordance, or LDL and ApoB disagreement.

Essentially, it means that two measurements which usually tell a similar story are now giving us different information.

There are two broad patterns worth understanding.

1. High ApoB, but LDL-C looks normal

Let’s say someone gets their cholesterol tested.

Their LDL-C is within the laboratory’s reference range. Nothing particularly concerning there.

But their ApoB is elevated.

What this could mean is that they have a larger number of cholesterol-carrying particles, even though the total amount of LDL cholesterol doesn’t look particularly high. In other words, LDL and ApoB disagreement may show that particle number is higher than LDL-C alone suggests.

Each particle may be carrying less cholesterol than expected, but there are more particles circulating. And since these particles can contribute to plaque buildup, the LDL-C result alone may underestimate their cardiovascular risk. Most people would probably look at a normal LDL-C value and move on.

We check whether something has been flagged, whether it’s too high or too low, and then decide if it needs attention. But reference ranges don’t always tell us how different markers relate to one another.

2. High LDL-C, but ApoB is relatively lower

Now consider the opposite.

Someone has high LDL-C, but their ApoB is lower than you might expect from that LDL-C result.

In this case, they may have fewer particles carrying a relatively larger amount of cholesterol each. Studies suggest that when LDL and ApoB disagreement appears, cardiovascular risk often aligns more closely with ApoB.

Does this mean a person with high LDL-C and relatively low ApoB can ignore their cholesterol?

No.

LDL cholesterol remains an important part of cardiovascular risk assessment and treatment. Particularly if someone has familial hypercholesterolemia, existing cardiovascular disease, or other significant risk factors. This is where interpreting health data gets interesting, and also slightly complicated.

The question is what these results tell us when we look at them together, along with everything else we know about a person’s health.

What does the research say?

Researchers have studied LDL-C and ApoB across large populations to understand which measurement is more closely associated with cardiovascular events.

A 2024 analysis of UK Biobank data looked at this directly. ApoB is very highly correlated with LDL-C and non-HDL-C, but among people with the same cholesterol values there’s still substantial variation in ApoB. And that variation tracked with outcomes. Comparing people with the same LDL-C, those whose ApoB sat more than one standard deviation above average had a 10-year cardiovascular event rate of around 7.3%, against around 4.0% for those more than one standard deviation below.

Once ApoB was included in the model, the extra information carried by LDL-C, non-HDL-C and triglycerides no longer reached significance. The reverse was not true. When LDL-C or non-HDL-C disagreed with ApoB, risk didn’t shift with them.

A separate analysis of 389,529 UK Biobank participants, combined with populations from secondary prevention trials, reached a similar conclusion. ApoB remained independently associated with myocardial infarction when LDL-C and triglycerides were accounted for.

And research from Denmark approached the question differently. In 53,484 women and 41,624 men from the Copenhagen General Population Study, none of them taking statins, researchers calculated “excess ApoB” – the amount of ApoB above what you’d predict from someone’s LDL-C alone. Over a median follow-up of 9.6 years, that excess was associated with heart attack and cardiovascular disease in a dose-dependent way, in both women and men. For men with 26 to 45 mg/dL of excess ApoB, the adjusted hazard ratio for cardiovascular disease was 1.41 compared with those who had very little excess.

What struck me is that this held across the entire LDL-C range. Including people whose LDL-C looked perfectly acceptable.

What about particle size?

Smaller particles appear to enter the arterial wall more easily, bind the LDL receptor less effectively, circulate for longer, and are more prone to oxidation.

But when researchers measured particle count, type and size directly in UK Biobank participants, the picture simplified. Total ApoB particle count was associated with coronary artery disease, with a hazard ratio of 1.33 per standard deviation. Particle size and subclass added essentially nothing once count was accounted for.

Which reframes the whole thing for me. The issue isn’t that the particles are small. It’s that there are more of them, and their smallness is precisely why a cholesterol-based test doesn’t notice.

Lipoprotein(a) was the one exception in that analysis. It stayed associated with coronary disease even after adjusting for ApoB particle count, with a hazard ratio of 1.18. I’ll come back to that.

Why Would ApoB Be High When LDL-C Is Normal?

But why does that happen in the first place?

A lot of it has to do with how our bodies produce, transport, and clear lipoprotein particles.

This is where metabolic health becomes relevant.

Discordance, particularly high ApoB with relatively normal LDL-C, is more commonly seen in people with:

• Elevated triglycerides

• Insulin resistance

• Type 2 diabetes

• Increased abdominal fat

• Metabolic syndrome

It can also appear in people taking certain cholesterol-lowering medications, and in those whose LDL-C has been brought to a very low level.

To understand why, we need to look at what happens in the liver.

The liver produces particles that transport triglycerides and cholesterol through the bloodstream. One of these is VLDL, or very-low-density lipoprotein.

When triglyceride metabolism is altered, the body may produce more triglyceride-rich particles.

What happens next is the part I had wrong initially. I’d assumed those particles simply get trimmed down. There’s an exchange step too. A protein called cholesteryl ester transfer protein moves cholesterol out of LDL particles in return for triglyceride moving in. Enzymes such as hepatic lipase then remove that triglyceride.

What’s left is a particle that is smaller and carries less cholesterol than it otherwise would. Not because it was never loaded, but because its cholesterol was effectively traded away.

The result can be a larger number of particles circulating without a corresponding increase in LDL-C.

And ApoB helps us identify that difference, which is exactly why LDL and ApoB disagreement can matter in clinical interpretation.

High triglycerides make this pattern more likely but aren’t a prerequisite. Cholesterol-depleted ApoB particles can be present at any triglyceride level, which is part of why the two measurements can part ways in people whose triglycerides look unremarkable.

Blood sugar regulation, insulin resistance, triglycerides, body composition, and lipid metabolism can all influence one another.

Let’s Look At Some Indian Data

The ICMR-INDIAB survey, which assessed 113,043 adults across the country, reported a dyslipidaemia prevalence of 81.2%, diabetes at 11.4%, prediabetes at 15.3%, and abdominal obesity at 39.5%. The metabolic conditions most associated with discordance are not edge cases here.

More specifically, one study compared 4,244 adults from a Delhi cohort with 11,778 participants in the US national survey. The Indian group had higher triglycerides and lower HDL-C, which I expected. Their total cholesterol, LDL-C and non-HDL-C were all significantly lower than the American group’s, while their ApoB was significantly higher.

More particles, each carrying less cholesterol. The exact pattern this article has been describing, measured in an Indian population.

There’s a practical consequence to this. In a survey of 3,047 adults in urban Delhi and rural Ballabhgarh, researchers worked out which ApoB values correspond to standard LDL-C targets. For an LDL-C target of 70 mg/dL, the matching ApoB was about 75 mg/dL in the overall group. In people with triglycerides above 150 mg/dL, it was about 93 mg/dL.

Which means that reaching an LDL-C target doesn’t automatically mean reaching the equivalent ApoB target, and the gap is widest in exactly the people most likely to have high triglycerides.

What If LDL-C Is High But ApoB Isn’t?

High LDL-C is still associated with cardiovascular disease, and lowering LDL-C has been shown to reduce cardiovascular events. That evidence is not in question, and it is what essentially every treatment decision in this field is built on.

So a relatively reassuring ApoB result doesn’t automatically cancel out an elevated LDL-C result. This becomes particularly relevant for people with inherited cholesterol disorders, existing heart disease, or a strong family history of cardiovascular problems.

There are other things to consider too. Blood pressure, blood glucose, age, medications, smoking, and previous health conditions all contribute to a person’s overall cardiovascular risk.

So what counts as a good ApoB number?

There isn’t a single LDL-C target. It depends on overall cardiovascular risk.

The National Lipid Association’s 2024 expert consensus suggests ApoB thresholds of about 90 mg/dL for people at borderline to intermediate risk, 70 mg/dL at high risk, and 60 mg/dL at very high risk.

The 2026 ACC/AHA guideline, which replaced the 2018 cholesterol guideline, sets ApoB goals that run alongside its LDL-C goals: broadly under 90 mg/dL at lower risk and under 70 mg/dL at higher risk, with under 55 mg/dL described as reasonable in severe hypercholesterolaemia with established cardiovascular disease.

Indian guidance is structured similarly. The Lipid Association of India’s targets, reflected in the Cardiological Society of India’s 2024 guidelines, work out to roughly under 90 mg/dL at low to moderate risk, under 80 mg/dL at high risk, and under 65 mg/dL or lower in the very high and extreme risk categories.

The useful thing about seeing these side by side is realising that none of them are describing a reference range. They’re treatment thresholds, tied to a risk category that someone has to assess first.

Which is a long way of saying that an ApoB number on its own doesn’t tell you very much. What it means depends on who it belongs to.

Should Everyone Get An ApoB Test?

This is where I think the conversation becomes more practical. Most routine lipid panels measure total cholesterol, LDL-C, HDL-C, and triglycerides.

And for many people, a standard lipid panel provides enough information to begin assessing cardiovascular risk. But there are situations where ApoB can add valuable context.

For example, someone might have high triglycerides, insulin resistance, diabetes, or other metabolic risk factors that make their LDL-C less representative of their atherogenic particle burden.

Someone already taking lipid-lowering medication may also benefit from understanding ApoB, depending on their clinical situation. Statins tend to lower LDL-C more than they lower ApoB, which means a person can reach their LDL-C goal while still carrying more particles than that number suggests.

What matters is that ApoB can add context when LDL-C does not tell the whole story, particularly in cases of LDL and ApoB disagreement or when standard lipid results do not match the wider risk pattern.

Where FOXO fits into this

One of the things we’re trying to do at FOXO is make preventive health information easier to understand and act on. With the FOXO Primer, ApoB is included alongside other biomarkers that help build a broader picture of a person’s health.

But getting more data is only part of the process. You still need to understand what the results mean, how they relate to one another, and whether there’s anything that needs attention.

For someone with elevated ApoB, that conversation might involve reviewing their lipid profile, glucose regulation, medical history, food habits, physical activity, and other cardiovascular risk factors. Depending on their risk, they may need lifestyle changes, medication, or a combination of both.

And whatever that plan looks like, it needs to be realistic.

I think we sometimes underestimate how difficult it is to consistently make changes to our daily routines. There are workdays, travel, family commitments, stress, and about a hundred other things competing for our time. It’s easy to create an ideal health routine on paper. Following it through is another matter.

This is also why ongoing guidance matters. Understanding a result is one thing. Knowing what to do with that information, following a plan, and reassessing progress over time is where preventive healthcare becomes part of everyday life.

How To Read LDL And ApoB Disagreement Results

If I were trying to understand a lipid report showing discordance between LDL-C and ApoB, these are the things I would want to know.

First, was the test done under the right conditions?

ApoB generally doesn’t change very much after a usual meal. Triglycerides do, and because most laboratories calculate LDL-C using the triglyceride value, that calculated LDL-C moves with them.

So I’d want to know whether the sample was fasting or non-fasting, and which equation the laboratory used to arrive at the LDL-C number. Indian guidelines now recommend non-fasting lipid measurement for routine risk estimation, which makes understanding this more useful, not less.

Second, what do the other lipid markers look like?

I wouldn’t want to interpret ApoB without looking at LDL-C, HDL-C, triglycerides, and non-HDL cholesterol. They’re related measurements, and together they can tell us more about how lipids are being transported in the blood.

Third, is the person already taking medication?

Statins and other lipid-lowering medicines can change LDL-C and ApoB, sometimes to different degrees. So the results need to be understood in the context of any existing treatment.

Fourth, what else do we know about their health?

Blood pressure, fasting glucose, HbA1c, family history, existing medical conditions, and lifestyle factors can all influence cardiovascular risk. A lipid result is only one part of that assessment.

And finally, what does ‘normal’ actually mean here?

A result sitting within a reference range doesn’t automatically mean the person has no risk.

And a result outside that range doesn’t automatically tell us how serious the problem is.

Clinical targets can differ depending on someone’s medical history and overall cardiovascular risk.

For example, the LDL-C target for someone who has already experienced a heart attack may be very different from the target for someone without established cardiovascular disease. Current guidelines put that difference at under 55 mg/dL for the highest-risk group, against under 100 mg/dL at borderline or intermediate risk.

So I’d want to understand what range or target is appropriate for that person, rather than looking only at the flag on the report.

And I think that’s an important part of preventive health.

We’re learning more about how different measurements relate to one another, what they can tell us about risk, and where they might help us make better-informed decisions.

Of course, knowing more doesn’t mean we can predict everything.

There will always be things we cannot account for. Genetics, age, existing disease, environmental factors, and a number of other influences affect our health in ways that aren’t always obvious.

But there are things we can measure, understand, and work on.

And sometimes, that starts with a fairly simple question.

Why are these two numbers different?

Frequently Asked Questions